Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Dravet Syndrome Market Trends Indicate Sustained Growth During the Forecast Period (2026–2036), Driven by Novel Treatment Approaches | DelveInsight

globenewswire.com
BIIB Biogen's Zorevunersen (STK-001) is an investigational therapy for Dravet syndrome with potential disease-modifying benefits and has received FDA designations, indicating positive development and market potential. HRMY Harmony Biosciences is developing Clemizole Hydrochloride (EPX-100) for Dravet syndrome. The article lists it among other drugs but provides no specific details on its development status or market outlook. XNCR Xencor is listed as a company with pipeline drugs for Dravet syndrome, but no specific drug or development details are provided, making sentiment assessment difficult. AZN AstraZeneca is mentioned in the context of Dravet syndrome pipeline drugs, but no specific drug or development details are provided, making sentiment assessment difficult. LLY Eli Lilly and Company is listed as a company with pipeline drugs for Dravet syndrome, but no specific drug or development details are provided, making sentiment assessment difficult. PFE Pfizer is listed as a company with pipeline drugs for Dravet syndrome, but no specific drug or development details are provided, making sentiment assessment difficult. REGN Regeneron Pharmaceuticals is listed as a company with pipeline drugs for Dravet syndrome, but no specific drug or development details are provided, making sentiment assessment difficult. NVS Novartis is listed as a company with pipeline drugs for Dravet syndrome, but no specific drug or development details are provided, making sentiment assessment difficult. TSLA Telsa is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. TAK Takeda is mentioned in the context of Epilepsy and Lennox-Gastaut Syndrome markets, but no specific drug or development details are provided, making sentiment assessment difficult. GSK GlaxoSmithKline is listed as a key company for the Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. JNJ Janssen Pharmaceuticals is listed as a key company for the Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. UCB UCB Pharma is listed as a key company for the Epilepsy market, but no specific drug or development details are provided, making sentiment assessment difficult. BHF Biohaven Pharmaceuticals is listed as a key company for the Epilepsy market, but no specific drug or development details are provided, making sentiment assessment difficult. PRAX Praxis Precision Medicines is listed as a key company for the Developmental and Epileptic Encephalopathies market, but no specific drug or development details are provided, making sentiment assessment difficult. XENE Xenon Pharmaceuticals is listed as a key company for the Epilepsy market, but no specific drug or development details are provided, making sentiment assessment difficult. AQST Aquestive Therapeutics is listed as a key company for the Epilepsy market, but no specific drug or development details are provided, making sentiment assessment difficult. TNDM Tandem Diabetes Care is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. INCY Incyte Corporation is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. MRK Merck & Co. is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. ABBV AbbVie is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. BMY Bristol Myers Squibb is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. AMGN Amgen is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. GILD Gilead Sciences is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. VRTX Vertex Pharmaceuticals is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. CRSP CRISPR Therapeutics is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. EDIT Editas Medicine is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. NTLA Intellia Therapeutics is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. SRPT Sarepta Therapeutics is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. ALNY Alnylam Pharmaceuticals is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. EXAS Exact Sciences is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. TEVA Teva Pharmaceutical Industries is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. AXSM Axsome Therapeutics is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. CYTK Cytokinetics is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. INSM Insmed is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. KODK Eastman Kodak is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. LPCN Lipocine is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. MNKD MannKind Corporation is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. NBIX Neurocrine Biosciences is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. NCLH Norwegian Cruise Line Holdings is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. ONCY OncoCyte Corporation is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. ORIC ORIC Pharmaceuticals is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. PBYI Prothena Corporation is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. PEGA Pegasystems is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. PLRX Palatin Technologies is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. PRGS Pergolas is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. QGEN Qiagen is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. RGNX Regeneron Pharmaceuticals is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. ROST Ross Stores is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. RYAAY Ryanair Holdings is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. SNOW Snowflake Inc. is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. SWKS Skyworks Solutions is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. SYK Stryker Corporation is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. TGT Target Corporation is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. TRMB Trimble Inc. is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. TXG 10x Genomics is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. ULTA Ulta Beauty is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. VRSK Verisk Analytics is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. WDC Western Digital is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. WVE Wave Life Sciences is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. XOM Exxon Mobil is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. ZBRA Zebra Technologies is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. ZNTL Zentalis Pharmaceuticals is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. ZTS Zoetis Inc. is mentioned in the context of Lennox-Gastaut Syndrome market, but no specific drug or development details are provided, making sentiment assessment difficult. STOK Stoke Therapeutics' Zorevunersen (STK-001) is an investigational therapy for Dravet syndrome with potential disease-modifying benefits and has received FDA designations, indicating positive development and market potential. IONS Ionis Pharmaceuticals is developing ION337 for Dravet syndrome. The article lists it among other drugs but provides no specific details on its development status or market outlook. MOMO Momotaro-Gene is listed as a company with pipeline drugs for Dravet syndrome, but no specific drug or development details are provided, making sentiment assessment difficult. BBAR Barinthus Biotherapeutics is listed as a company with pipeline drugs for Dravet syndrome, but no specific drug or development details are provided, making sentiment assessment difficult. CTXR Cantex Pharmaceuticals is listed as a key company for the Developmental and Epileptic Encephalopathies Clinical Trial Analysis, but no specific drug or development details are provided, making sentiment assessment difficult. MBIO Mustang Bio is listed as a key company for the Developmental and Epileptic Encephalopathies Clinical Trial Analysis, but no specific drug or development details are provided, making sentiment assessment difficult. GNS Genenta Science is listed as a key company for the Developmental and Epileptic Encephalopathies Clinical Trial Analysis, but no specific drug or development details are provided, making sentiment assessment difficult. NEON NEONC Technologies is listed as a key company for the Developmental and Epileptic Encephalopathies Clinical Trial Analysis, but no specific drug or development details are provided, making sentiment assessment difficult. OVID Ovid Therapeutics is listed as a key company for the Epilepsy market, but no specific drug or development details are provided, making sentiment assessment difficult. BHVN Biohaven Pharmaceuticals is listed as a key company for the Epilepsy market, but no specific drug or development details are provided, making sentiment assessment difficult.

Dravet Syndrome Market Trends Indicate Sustained Growth During the Forecast Period (2026–2036), Driven by Novel Treatment Approaches | DelveInsight New York, USA, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Dravet Syndrome Market Trends Indicate Sustained Growth During the Forecast Period (2026–2036), Driven by Novel Treatment Approaches | DelveInsight

The Dravet syndrome market is poised for steady growth, driven by increasing disease awareness, earlier genetic diagnosis, and the expanding adoption of targeted anti-seizure therapies. The introduction of innovative treatments, including Zorevunersen (STK-001) (Stoke Therapeutics and Biogen), Bexicaserin (LP352) (Lundbeck), Clemizole Hydrochloride (EPX-100) (Harmony Biosciences), ETX101 (Encoded Therapeutics), and others, is expected to improve patient outcomes and expand the treatment landscape.

Recently published Dravet Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Dravet syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Dravet Syndrome Market Summary

Discover Dravet syndrome latest research 2026 @ https://www.delveinsight.com/report-store/dravet-syndrome-market

Key Factors Driving the Growth of the Dravet Syndrome Market

Aparna Thakur, Project Manager of Forecasting at DelveInsight, said that gene therapies such as Encoded Therapeutics’ ETX101 and antisense oligonucleotides such as Stoke Therapeutics and Biogen’s Zorevunersen (STK-001) are expected to drive the next wave of innovation with potential disease-modifying benefits, while serotonergic agents and established anti-seizure medications will continue to support near-term market growth.

Dravet Syndrome Market Analysis

Learn more about the Dravet syndrome therapeutics market @ US Dravet Syndrome Market

Dravet Syndrome Competitive Landscape

Some of the Dravet syndrome drugs under development include Zorevunersen (STK-001) (Stoke Therapeutics and Biogen), Bexicaserin (LP352) (Lundbeck), Clemizole Hydrochloride (EPX-100) (Harmony Biosciences), ETX101 (Encoded Therapeutics), BMB-101 (Bright Minds Bio), BL-001 (Bloom Science), NT102 (Neuroene Therapeutics), ION337 (Ionis), EMU003 (Emugen Therapeutics), RT101 (Regel Therapeutics), and others.

Stoke Therapeutics and Biogen’s Zorevunersen (STK-001) is an investigational therapy being studied in ongoing clinical trials for the treatment of Dravet syndrome. The therapy is intended to increase NaV1.1 protein production by utilizing the healthy (wild-type) copy of the SCN1A gene, aiming to restore normal physiological NaV1.1 levels. This approach has the potential to reduce seizure frequency while also addressing major non-seizure complications associated with the disorder. The therapy has received both Rare Pediatric Disease Designation and Breakthrough Therapy Designation from the FDA for patients with Dravet syndrome carrying confirmed SCN1A mutations that are not linked to gain-of-function variants.

Encoded Therapeutics is advancing ETX101, an investigational, one-time gene regulation therapy designed to modify the course of SCN1A-positive Dravet syndrome. As the company's lead candidate, ETX101 targets the underlying genetic cause of the disease by selectively regulating gene expression in affected cells. The therapy is being developed to improve not only seizure control but also the cognitive, behavioral, developmental, and motor impairments associated with Dravet syndrome. According to the company's development pipeline, ETX101 is currently in the early stages of clinical evaluation.

The anticipated launch of these emerging Dravet syndrome therapies are poised to transform the Dravet syndrome market landscape in the coming years. As these cutting-edge Dravet syndrome therapies continue to mature and gain regulatory approval, they are expected to reshape the Dravet syndrome market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

To know more about the Dravet syndrome treatment market, visit @ Dravet Syndrome Therapeutic Market

Recent Developments in the Dravet Syndrome Market

Dravet Syndrome Epidemiology Segmentation

The Dravet syndrome epidemiology section provides insights into the historical and current Dravet syndrome patient pool and forecasted trends for the leading markets. In the 7MM, the US accounted for the highest share (~50%) of diagnosed prevalent cases of Dravet syndrome in 2025.

The Dravet syndrome market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets segmented into:

Download the report to understand the future of Dravet syndrome treatment @ Dravet Syndrome Treatment Options

Scope of the Dravet Syndrome Market Report

Discover more about next-generation Dravet syndrome drugs @ Dravet Syndrome Clinical Trials

Table of Contents

Related Reports

Dravet Syndrome Clinical Trial Analysis

Dravet Syndrome Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Dravet syndrome companies, including Hinova Pharmaceuticals, Lantheus, Janux Therapeutics, Tagworks Pharmaceuticals, AstraZeneca, Xencor, Cardiff Oncology, Madison Vaccines, Bayer, Olema Oncology, Eli Lilly and Company, Curium, Pfizer, Regeneron Pharmaceuticals, PendreaBio, Momotaro-Gene, Norroy Bioscience, Orion Corporation, Epizyme, Barinthus Biotherapeutics, Twinpig Biolab, Oxford Vacmedix, Roche, ImaginAb, Halda THERAPEUTICS, Novartis, Kyinno Biotechnology, and others.

Developmental and Epileptic Encephalopathies Market

Developmental and Epileptic Encephalopathies Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key DEE companies including Ultragenyx Pharmaceutical, Oak Hill Bio, Roche, Praxis Precision Medicines, Longboard Pharmaceuticals (acquired by Lundbeck), Stoke Therapeutics, Praxis Precision Medicines, Harmony Biosciences, SK Life Science (Subsidiary of SK Biopharmaceuticals), Ionis Pharmaceuticals, Encoded Therapeutics, Cerecin Neurosciences, Oils4Cure, Bright Minds Biosciences, and others.

Developmental and Epileptic Encephalopathies Clinical Trial Analysis

Developmental and Epileptic Encephalopathies Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key DEE companies, including Denovo Biopharma, Cantex Pharmaceuticals, CNS Pharmaceuticals, CANbridge Pharmaceuticals, Vaximm, Inovio Pharmaceuticals, Mustang Bio, Bullfrog AI Holdings, Cantex, Chimeric Therapeutics, Philogen, Boehringer Ingelheim, Photonamic GmbH, Berg Pharma, Beyond Bio, Genenta Science, Polaris Pharmaceuticals, Telix Pharmaceuticals, Shanghai Simnova Biotechnology, NEONC Technologies, and others.

Epilepsy Market

Epilepsy Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key epilepsy companies including Xenon Pharmaceuticals, Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Takeda, Ovid Therapeutics, SK Biopharmaceuticals (SK Life Science), Eisai, Biohaven Pharmaceuticals, Knopp Biosciences, UCB Pharma, Alexza Pharmaceuticals, Neurocrine Biosciences, Idorsia Pharmaceuticals, Equilibre Biopharmaceuticals, and others.

Lennox–Gastaut Syndrome Market

Lennox–Gastaut Syndrome Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key LGS companies, including GlaxoSmithKline, Meda Pharmaceuticals, Roche, Lundbeck, Greenwich Biosciences, Janssen Pharmaceuticals, Eisai, Zogenix, Takeda, Ovid Therapeutics, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.